doublestrand
short
interf
rna
sirna
induc
posttranscript
gene
silenc
varieti
metazoan
cell
tissu
success
use
synthet
sirna
target
cellular
viral
gene
cell
cultur
open
door
sirna
prospect
antivir
drug
gene
therapi
firstgener
sirna
design
mimic
product
dicer
endonucleas
cleavag
long
duplex
overhang
contain
natur
unmodifi
ribos
base
report
us
numer
laboratori
sirna
prove
effect
cell
cultur
anim
particular
mention
antivir
activ
sirna
see
chapter
first
document
us
respiratori
syncyti
viru
rsv
proofofconcept
studi
synthet
unmodifi
sirna
design
essenti
viral
gene
prevent
rsv
growth
cultur
lung
epitheli
cell
translat
success
anim
model
reason
logic
rout
deliveri
sirna
nose
intranas
first
noninvas
second
involv
rel
simpl
applic
procedur
nasal
drop
aerosol
inhal
third
sirna
drug
follow
rout
viru
reach
tissu
includ
lung
lastli
subsequ
result
show
intranas
administ
sirna
remain
lung
leach
blood
tissu
minim
risk
system
side
effect
data
shown
chapter
therefor
focus
intranas
deliveri
antirespiratori
viral
sirna
first
summar
progress
made
four
major
respiratori
virus
rsv
parainfluenza
viru
piv
influenza
viru
flu
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
first
three
virus
clinic
signific
claim
larg
number
human
live
year
throughout
world
annual
flu
epidem
alon
affect
us
popul
averag
hospit
partli
due
high
mutat
rate
rna
genom
definit
vaccin
reliabl
antivir
treatment
virus
ribavirin
ifn
although
sometim
use
rel
nonspecif
toxic
regard
molecular
featur
genom
rsv
piv
nonseg
negativestrand
rna
virus
belong
differ
genera
paramyxovirida
famili
flu
orthomyxoviru
contain
segment
negativestrand
rna
genom
coronovirus
sarscov
contain
positivestrand
envelop
rna
genom
common
among
rna
virus
encod
gene
rnadepend
polymeras
rdrp
transcrib
replic
genom
host
anim
cell
devoid
activ
mani
potent
antivir
sirna
therefor
target
viral
gene
code
rdrp
subunit
relat
rdrp
function
includ
eg
p
phosphoprotein
l
larg
see
tabl
n
nucleocapsid
gene
rsv
p
l
gene
piv
pa
n
gene
flu
replicas
gene
sarscov
case
sirna
design
essenti
viral
gene
optim
cell
cultur
use
intranas
appropri
anim
model
antivir
activ
shown
rsv
parainfluenza
viru
piv
use
balbc
mous
model
well
studi
sirna
deliv
complex
either
oligofectamin
invitrogen
carlsbad
ca
miru
transit
tko
reagent
see
sect
although
uncomplex
intranas
sirna
also
show
signific
efficaci
compar
untreat
mice
intranas
sirna
complex
oligofectamin
polyethyleneimin
pei
also
protect
highli
pathogen
influenza
virus
subtyp
mice
notwithstand
success
activ
sirna
transient
last
day
therefor
enhanc
intracellular
extracellular
stabil
synthet
sirna
increas
without
compromis
rnai
activ
continu
goal
therapeut
translat
rnai
varieti
chemic
modif
includ
termin
intern
one
ad
firstgener
sirna
sequenc
improv
stabil
deliveri
lead
call
secondgener
sirna
advantag
taken
free
group
ribos
moieti
rna
contrast
dna
lack
oh
group
variou
substitu
ad
pursu
two
promis
one
name
latter
modif
place
pyrimidin
nucleosid
c
u
lead
residu
number
previou
studi
substitut
introduc
variou
extent
antisens
strand
guid
strand
strand
sirna
shown
enhanc
stabil
potenc
although
intranas
applic
test
addit
tend
reduc
sirnadriven
innat
immun
respons
systemat
studi
cell
cultur
biochem
function
activ
sirna
vindic
found
affect
posit
modif
sequenc
gener
speak
modifi
ribonucleotid
antisens
strand
less
activ
rel
one
intern
gener
welltoler
antisens
strand
show
signific
shift
activ
depend
posit
contrast
incorpor
sens
strand
sirna
show
strong
posit
prefer
comprehens
studi
howev
intern
modif
either
strand
actual
made
sirna
less
activ
anim
experi
residu
sirna
hepat
b
viru
substitut
administ
intraven
iv
lipid
complex
sirna
show
improv
efficaci
longer
halflif
plasma
liver
sirna
addit
reveal
accumul
liver
spleen
lung
explain
success
iv
administr
hepat
suggest
ineffect
rout
lung
infect
base
absenc
uniform
pattern
studi
reason
substitut
secondgener
sirna
respiratori
virus
individu
optim
follow
step
design
firstgener
sirna
follow
gener
accept
sequenc
rule
ii
select
one
lowest
prefer
nm
cell
cultur
assay
viru
growth
iii
add
ome
f
substitut
variou
format
ie
number
placement
iv
ensur
substitut
either
improv
reduc
knockdown
effici
screen
cell
cultur
v
confirm
efficaci
lack
toxic
anim
model
vi
test
improv
stabil
serum
blood
vitro
final
deem
necessari
resourc
permit
low
highthroughput
assay
offtarget
effect
perform
ensur
target
specif
present
consensu
procedur
test
laboratori
follow
step
essenti
protocol
use
test
modif
long
synthet
chemistri
avail
synthet
sirna
chosen
sequenc
lyophil
purchas
without
modif
nmol
dharmacon
lafayett
co
select
effect
sirna
purchas
modif
variou
format
dharmacon
sens
antisens
strandsrnasefre
art
aerosol
resist
pipet
tip
molecular
bioproduct
san
diego
ca
rnasefre
microfug
tube
ambion
austin
tx
sirna
buffer
mm
kcl
mm
hepeskoh
ph
mm
usual
suppli
sirna
manufactur
dharmacon
stock
dilut
need
assum
reader
access
appropri
cell
cultur
facil
consist
incub
cultur
hood
avail
expertis
viru
growth
assay
chapter
cover
specif
issu
relat
test
antivir
sirna
rsv
common
respiratori
virus
rsv
piv
human
influenza
biosafeti
level
pathogen
obey
institut
regul
follow
materi
need
suitabl
cell
line
eg
cell
rsvstandard
cell
cultur
media
rsv
host
cell
line
grow
virtual
cell
cultur
media
use
dmem
glucos
supplement
glutamin
fetal
bovin
serum
heatinactiv
without
penicillinstreptomycinstandard
dispos
steril
plastic
ware
cell
cultur
balbc
mice
week
old
weigh
g
charl
river
laboratori
wilmington
five
mgml
sodium
pentobarbit
nembut
singleus
hypoderm
needl
vwr
west
chester
pa
one
cc
singleus
syring
bd
luerlok
tip
vwr
transittko
sirna
transfect
reagent
miru
bio
corpor
madison
wi
optimem
reduc
serum
medium
gibco
invitrogen
corpor
carlsbad
ca
rnasefre
gelload
microcapillari
tip
vwr
rnasefre
microfug
tube
ambion
use
free
onlin
sirna
design
program
target
mrna
sequenc
see
note
gener
use
one
avail
whitehead
institut
mit
server
follow
url
http
jurawimitedubiocsirnaext
registr
requir
free
copi
past
target
sequenc
box
initi
choos
recommend
pattern
usual
need
chang
filter
criteria
ie
leav
default
click
search
button
rsv
l
gene
found
mani
prospect
one
tabl
sirna
obtain
gene
sequenc
repeat
procedur
time
choos
lead
tabl
prospect
sirna
sequenc
order
accord
thermodynam
valu
default
set
goal
select
sequenc
high
neg
valu
ie
sequenc
closer
top
tabl
addit
visual
examin
central
part
ie
ignor
first
two
last
two
nucleotid
pick
one
atrich
right
hand
side
gcrich
left
hand
side
number
sequenc
one
test
realli
depend
avail
resourc
order
least
given
target
order
sens
strand
antisens
strand
part
complementari
sequenc
provid
exampl
test
function
sirna
sequenc
base
l
polymeras
gene
rsv
tabl
assum
receiv
sirna
roughli
week
order
purchas
smallest
amount
initi
save
money
nmol
eachaft
receiv
lyophil
rna
nmol
briefli
spin
tube
ensur
rna
bottom
add
sirna
buffer
rna
pipett
solut
time
avoid
introduct
bubblesplac
solut
orbit
mixershak
min
room
temperatur
complet
mix
briefli
centrifug
tube
contain
sirna
ensur
solut
collect
bottom
tubecombin
volum
complementari
strand
rna
vortex
centrifug
add
sirna
buffer
make
mixheat
mixtur
minremov
heat
centrifug
briefli
sallow
solut
cool
room
temperatur
min
allow
format
doublestrand
sirna
readi
use
sirna
concentr
stock
solut
see
note
aliquot
sirna
small
volum
store
best
result
freezethaw
tube
four
time
trypsin
cell
seed
cell
complet
growth
medium
per
well
plate
incub
h
achiev
confluenc
immedi
transfect
add
optimem
steril
eppendorf
tube
add
transittko
reagent
mix
thoroughli
vortex
incub
room
temperatur
mindilut
sirna
mix
stock
sirna
buffer
test
three
concentr
sirna
concentr
least
duplic
possibl
triplic
final
concentr
correspond
volum
nm
nm
nm
add
volum
dilut
transfect
reagent
made
step
mix
gentl
pipet
incub
room
temperatur
minadjust
medium
volum
well
cell
monolay
step
remov
half
origin
volum
add
transfectionreadi
sirna
mixtur
step
dropwis
cell
gentli
tilt
rock
plate
evenli
distribut
complexesincub
h
cell
cultur
incubatoradd
challeng
viru
cell
rsv
add
virion
stock
pfuml
well
sirna
concentr
keep
uninfect
well
control
check
sirna
caus
cellular
death
offtarget
effect
incub
anoth
h
viru
growth
monitor
western
blot
anoth
h
viru
growth
monitor
extracellular
titer
latter
replac
old
media
equal
volum
fresh
prewarm
media
better
viru
growth
western
remov
media
wash
monolay
ml
pb
twice
add
sd
sampl
buffer
scrap
monolay
mix
well
pipet
boil
analyz
sdspage
western
antirsv
antibodi
titer
collect
media
well
expect
pfuml
uninhibit
cell
lower
sirna
work
well
serial
dilut
sampl
accordingli
fresh
complet
medium
plate
either
monolay
incub
h
count
plaqu
microscop
magnif
take
averag
triplic
plaqu
assay
sampleselect
effect
sirna
sequenc
strongest
antivir
effect
candid
modif
reason
mention
introduct
univers
consensu
regard
format
thu
guidelin
offer
consid
suggest
although
sequenc
shown
test
work
tabl
reader
encourag
conduct
exhaust
modif
test
sequenc
resourc
permitintroduc
modif
site
sens
strand
initi
tri
less
extens
modif
variou
posit
sometim
effectiveintroduc
altern
modif
sens
antisens
strand
start
avail
c
u
follow
sens
strand
reciproc
antisens
strand
tabl
order
modifi
sirna
commerci
sourc
eg
dharmacon
process
step
sect
prior
intranas
administr
sirna
mous
see
note
must
anesthet
use
standard
procedur
avail
laboratori
eg
administ
nembut
via
intraperiton
ip
inject
recommend
drug
dosag
mice
mgkg
see
note
gentli
lift
mous
tail
place
cage
lidgrip
loos
skin
neck
immobil
head
mous
extend
tail
draw
skin
tight
abdomen
grip
tail
littl
fingerhold
mous
headdown
posit
disinfect
inject
site
lower
right
left
quadrant
abdomen
use
hypoderm
needl
administ
anesthet
mous
readi
sirna
administr
voluntari
movement
observedplac
anesthet
mous
lab
towel
face
head
immobil
insert
microcapillari
tip
contain
sirnatransfect
reagent
complex
see
note
nostril
use
rang
nmol
sirna
per
mous
eg
nmol
instil
solut
slowli
min
period
allow
anim
breath
liquid
see
note
return
mous
cage
monitor
least
min
avoid
depress
cardiac
andor
respiratori
functionstest
desir
rnai
effect
appropri
interv
antivir
studi
instil
viru
nostril
well
human
rsv
infect
mice
well
use
viru
particl
per
anim
measur
standard
lung
titer
assay
andor
clinic
symptom
bodi
weight
respir
rate
etc
see
note
recent
rel
larg
nt
long
doublestrand
rna
act
dicer
substrat
dsirna
shown
potent
regular
sirna
use
also
found
least
potent
first
second
gener
sirna
term
intranas
antirsv
activ
without
increas
immun
reaction
data
shown
preliminari
experi
also
lent
well
modif
intranas
antivir
activ
data
shown
recommend
exact
format
optim
sequenc
follow
publish
dsirna
design
guidelin
although
describ
laboratori
mous
model
intranas
dosag
deliveri
easili
scale
laboratori
animalssirna
concentr
pharmaceut
industri
prefer
express
drug
concentr
wtvol
wtbodi
weight
eg
mgkg
research
howev
easier
use
express
sirna
concentr
molar
unit
eg
nm
sinc
allow
direct
comparison
potenc
differ
sirna
even
differ
base
composit
modif
henc
formula
weight
nake
sirna
without
transfect
reagent
without
chemic
modif
seem
potent
reagentcomplex
sirna
intranas
antivir
test
although
mechan
entri
unknown
sinc
nake
sirna
would
free
reagent
toxic
worth
test
modifi
secondgener
sirna
nake
applic
well
recommend
use
pei
appar
toxic
intranas
applic
avoid
use
excess
liquid
may
suffoc
anim
caus
death
rule
keep
total
instil
volum
balbc
mice
higher
volum
may
toler
larger
speciesth
protocol
describ
may
modifi
aerosol
sirna
use
enclosur
hous
anesthet
anim
handheld
nebul
common
type
use
inhal
asthmat
larger
amount
sirna
need
fraction
aerosol
actual
inhal
anim
use
routin
consid
optim
commerci
motor
nebul
check
local
pediatrician
exact
model
vendor
usag
modifi
system
remov
facial
mask
deliveri
end
insert
tube
directli
enclosur
snug
fit
mask
reduc
sirna
wast
